BRUSA HyPower, an innovative global supplier of power conversion systems for heavy-duty applications, has announced a minority investment by Bosch Rexroth, M&G Investments and Temasek. The investment aims to accelerate product development and
Tags :Reto Heuberger
Dufry has announced that it has entered into an agreement with the Italian company Edizione to collaborate with Autogrill to create a new integrated global travel experience. The combined company will serve more than 2.3 billion
DKSH Holding has announced the acquisition of Swiss Refarmed Group, strengthening its capabilities in the life sciences. Through the acquisition, DKSH Business Unit Performance Materials, the leading global distributor of innovative pharmaceutical ingredients synthesis and
Ginkgo Bioworks, a horizontal platform for cell programming, entered into a definitive purchase agreement to acquire FGen, a Swiss company specializing in strain development and optimization. Ginkgo Bioworks believes that FGen’s technology will significantly
Bosch Service Solutions, a provider of technology-based services, has planned to acquire Elpro Group, headquartered in Buchs, Switzerland. Founded in 1986, Elpro Group develops monitoring solutions for the pharmaceutical, biotech, life science and healthcare industries. With
CSL Limited, a global biotechnology company based in Australia and Vifor Pharma, a Swiss-based global pharmaceutical company, entered into an agreement for CSL to launch an all-cash public tender offer to acquire all publicly held
Novartis has entered into an agreement to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a consideration of USD 20.7 billion. Novartis had acquired the stake between 2001 and 2003 for approximately USD 5
Kohlberg Kravis Roberts & Co (KKR), a global investment firm, and Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company, have entered into an agreement where KKR will acquire Biosynth Carbosynth
Archlet, an AI-based sourcing platform startup and ETH Zürich spin-off, just closed its USD 10M Series A Financing Round. The round was led by the European venture capitalist HV Capital. The existing investors, including
ADC Therapeutics, a Lausanne-based commercial-stage oncology-focused biotechnology company, has entered into a royalty purchase agreement with HealthCare Royalty. Under the agreement, ADC Therapeutics will receive up to USD 325 million. Initial payment of USD 225 million upon
